Advertisement
UK markets close in 6 hours 40 minutes
  • FTSE 100

    8,091.42
    +51.04 (+0.63%)
     
  • FTSE 250

    19,710.43
    -8.94 (-0.05%)
     
  • AIM

    754.95
    +0.26 (+0.03%)
     
  • GBP/EUR

    1.1672
    +0.0027 (+0.24%)
     
  • GBP/USD

    1.2523
    +0.0060 (+0.48%)
     
  • Bitcoin GBP

    50,917.33
    -2,291.36 (-4.31%)
     
  • CMC Crypto 200

    1,360.93
    -21.64 (-1.56%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    83.15
    +0.34 (+0.41%)
     
  • GOLD FUTURES

    2,339.80
    +1.40 (+0.06%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,994.78
    -93.92 (-0.52%)
     
  • CAC 40

    8,063.95
    -27.91 (-0.34%)
     

Novartis Launches FocalView to Modernize Clinical Trials

Novartis Launches FocalView to Modernize Clinical Trials

Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.